Moreover, treatment with MSCs significantly decreased col1 transcripts, with beneficial trends of profibrogenic gene expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) and MMP-2, 8, and 9 (Fig. 4h, i), confirming that MSC infusions significantly attenuated T2DM-induced liver disease. The gene discussed is MMP2; the disease is type 2 diabetes mellitus.